drugset / Trial / NCT04878107
SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy
RandomizedSequentialOpen-labelTreatment
Summary
SABRE STUDY will explore effectiveness and safety of the combination therapy of camrelizumab，apatinib and SBRT/LDRT in patients with metastatic non-small Cell Lung Cancer (NSCLC) patient previously treated With PD-1/L1 Inhibitor and Chemotherapy.
Timeline
- Start
- 2022-03-15
- Primary completion
- 2022-10
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 250 mg | — |